

## DAFTAR PUSTAKA

- Adler, M.W., 1996. Perkembangan Epidemiologi, dalam: *Petunjuk Penting AIDS (ABC of AIDS)*. Penerbit Buku Kedokteran EGC, Jakarta.
- Amin, J., Boyd, M.A., Kumarasamy, N., Moore, C.L., Losso, M.H., Nwizu, C.A., dkk., 2015. Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. *PLOS ONE*, **10**: e0118228.
- Anonim, 2007. 'Hasil Monitoring 25 RS Rujukan Pelayanan Kesehatan ODHA Direktur Jenderal Pelayanan Medik Departemen Kesehatan RI', *Yayasan Mitra INTI*. URL: <http://www.mitrinti.org/?q=node/340> (diakses tanggal 6/2/2018).
- Anonim, 2017. 'DynaMed Plus® The Next-generation , Evidence-based Clinical Information Resource, Designed to Optimize Time to Answer', *EBSCO*. URL: [https://www.ebscohost.com/assets-ebrochures/DynaMed-Plus-eBrochure.pdf?\\_ga=2.252662543.721294030.1525794474-884887223.1525204792](https://www.ebscohost.com/assets-ebrochures/DynaMed-Plus-eBrochure.pdf?_ga=2.252662543.721294030.1525794474-884887223.1525204792) (diakses tanggal 1/6/2018).
- Arnedo, M., Alonso, E., Eisenberg, N., Ibanez, L., Ferreyra, C., Jaen, A., dkk., 2012. Monitoring HIV Viral Load in Resource Limited Settings: Still a Matter of Debate? *PLoS ONE*, **7**: e47391.
- Astuti, W. dan Rayasari, F., 2017. Pengalaman Seksual Pasangan Penderita HIV dalam Mempertahankan Status HIV Negatif di RSPI Prof. Dr. Sulianti Saroso. *Indonesian Journal of Nursing Practices*, **1**: 32–43.
- Bartlett, J. (Editor), 2012. CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. *PLoS Medicine*, **9**: e1001194.
- Barus, T., Anwar, Y., dan Ginting, D., 2017. Evaluasi Efek Samping Obat Antiretroviral dan Penatalaksanaanya pada Pasien HIV/AIDS di Puskesmas Kecamatan Penjaringan Jakarta Utara Periode Tahun 2013 – 2015. *Social Clinical Pharmacy Indonesia Journal*, **2**: 29–37.
- Benn, P., Sauret-Jackson, V., Cartledge, J., Ruff, C., Sabin, C., Moyle, G., dkk., 2009. Improvements in Cheek Volume in Lipotrophic Individuals Switching Away from Thymidine Nucleoside Reverse Transcriptase Inhibitors. *HIV Medicine*, **10**: 351–355.
- Berrada, S., Mkandawire, T., Kamungoma-Dada, I., Njuho, P., Thipa, N., Pinini, Z., dkk., 2013. 'What are The Reasons for Switching ART Patients to Second-Line Regimen in Public Healthcare Settings in Gauteng? Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program', . Management Sciences for Health, Arlington, VA.

- Besral, B., Utomo, B., dan Zani, A.P., 2004. Potensi Penyebaran HIV dari Pengguna NAPZA Suntik ke Masyarakat Umum. *Makara Kesehatan*, **8**: 53–58.
- Bezabhe, W.M., Bereznicki, L.R., Chalmers, L., Gee, P., Kassie, D.M., Bimirew, M.A., dkk., 2015. Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study From Ethiopia. *Drug Safety*, **38**: 629–639.
- Biewenga, J., Keung, C., Solanki, B., Natarajan, J., Leitz, G., Deleu, S., dkk., 2015. Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy Volunteers: Clinical Pharmacology in Drug Development. *Clinical Pharmacology in Drug Development*, **4**: 41–48.
- BNN, 2004. Biaya Ekonomi dan Sosial Penyalahgunaan Narkoba di Indonesia, dalam: *Himpunan Hasil Penelitian Badan Narkotika Nasional 2003 Dan 2004*. Badan Narkotika Nasional, Jakarta.
- Boettiger, D.C., Nguyen, V.K., Durier, N., Bui, H.V., Heng Sim, B.L., Azwa, I., dkk., 2015. Efficacy of Second-Line Antiretroviral Therapy Among People Living With HIV/AIDS in Asia: Results From the TREAT Asia HIV Observational Database. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, **68**: 186–195.
- Bor, J., Herbst, A.J., Newell, M.-L., dan Barnighausen, T., 2013. Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-up of HIV Treatment. *Science*, **339**: 961–965.
- Boyd, M.A., Moore, C.L., Molina, J.-M., Wood, R., Madero, J.S., Wolff, M., dkk., 2015. Baseline HIV-1 Resistance, Virological Outcomes, and Emergent Resistance in the SECOND-LINE Trial: an Exploratory Analysis. *The Lancet HIV*, **2**: e42–e51.
- Bunupuradah, T., Chetchotisakd, P., Ananworanich, J., Munsakul, W., Jirajariyavej, S., Kantipong, P., dkk., 2012. A Randomized Comparison of Second-Line Lopinavir/Ritonavir Monotherapy vs. Tenofovir/Lamivudine/Lopinavir/Ritonavir in Patients Failing NNRTI-Regimens: The HIV STAR Study. *Antiviral Therapy*, **17**: 1351–1361.
- Bunyamin, J., 2014. 'Association between Stavudin Administration with Lipodystrophy and Dyslipidemia among HIV-infected Patients in Dr. Kariadi Hospital Semarang', , *Skripsi, S. Ked.*, . Universitas Diponegoro, Semarang.
- Castro, K.G., Ward, J.W., Slutsker, L., Buehler, J.W., Jaffe, H.W., dan Berkelman, R.L., 1992. '1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults', . URL: <https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm> (diakses tanggal 28/3/2018).
- Chakravarty, J., Sundar, S., Chourasia, A., Singh, P.N., Kurle, S., Tripathy, S.P., dkk., 2015. Outcome of Patients on Second Line Antiretroviral Therapy Under Programmatic Condition in India. *BMC infectious diseases*, **15**: 517.

- Charbonneau, D.H. dan James, L.N., 2018. DynaMed Plus®: An Evidence-Based Clinical Reference Resource. *Medical Reference Services Quarterly*, **37**: 168–176.
- Chastain, D.B., Stover, K.R., dan Riche, D.M., 2017. Evidence-Based Review of Statin Use in Patients with HIV on Antiretroviral Therapy. *Journal of Clinical & Translational Endocrinology*, **8**: 6–14.
- Chauvin, B., Drouot, S., Barrail-Tran, A., dan Taburet, A.-M., 2013. Drug–Drug Interactions between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. *Clinical Pharmacokinetics*, **52**: 815–831.
- Chodidjah, S., Agustini, N., dan Ungsianik, T., 2004. Hubungan antara Pengetahuan tentang HIV/AIDS dengan Perilaku Seksual Pranikah pada Remaja. *Jurnal Keperawatan Indonesia*, **8**: 50–53.
- Ciaffi, L., Koulla-Shiro, S., Sawadogo, A., le Moing, V., Eymard-Duvernay, S., Izard, S., dkk., 2015. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. *AIDS (London, England)*, **29**: 1473–1481.
- Collier, D., Iwuji, C., Derache, A., de Oliveira, T., Okesola, N., Calmy, A., dkk., 2017. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **64**: 1006–1016.
- Collins, I.J., Foster, C., Kahlert, C., Smit, C., Goodall, R., Marques, L., dkk., 2018. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand. *Clinical Infectious Diseases*, **66**: 594–603.
- Curran, A. dan Ribera, E., 2011. From Old to New Nucleoside Reverse Transcriptase Inhibitors: Changes in Body Fat Composition, Metabolic Parameters and Mitochondrial Toxicity After the Switch from Thymidine Analogs to Tenofovir or Abacavir. *Expert Opinion on Drug Safety*, **10**: 389–406.
- Dahlan, M.S., 2014. *Statistik Untuk Kedokteran Dan Kesehatan : Deskriptif, Bivariat, Dan Multivariat Dilengkapi Aplikasi Menggunakan SPSS*, Edisi Keenam. ed. Epidemiologi Indonesia, Jakarta.
- Damtie, D., Yismaw, G., Woldeyohannes, D., dan Anagaw, B., 2013. Common Opportunistic Infections and Their CD4 Cell Correlates among HIV-infected Patients Attending at Antiretroviral Therapy Clinic of Gondar University Hospital, Northwest Ethiopia. *BMC Research Notes*, **6**: 534.
- Danion, F., Aguilar, C., Catherinot, E., Alanio, A., DeWolf, S., Lortholary, O., dkk., 2015. Mucormycosis: New Developments into a Persistently Devastating Infection. *Seminars in Respiratory and Critical Care Medicine*, **36**: 692–705.
- De Luca, A., Sidumo, Z.J., Zanelli, G., Magid, N.A., Luhanga, R., Brambilla, D., dkk., 2017. Accumulation of HIV-1 Drug Resistance in Patients on a Standard Thymidine Analogue-Based First Line Antiretroviral Therapy After Virological Failure: Implications for the Activity of Next-Line

- Regimens from a Longitudinal Study in Mozambique. *BMC Infectious Diseases*, **17**: 605.
- de Waal, R., Cohen, K., dan Maartens, G., 2013. Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction. *PLoS ONE*, **8**: e63623.
- Decloedt, E.H., Maartens, G., Smith, P., Merry, C., Bango, F., dan McIlleron, H., 2012. The Safety, Effectiveness, and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy. *PLoS ONE*, **7**: e32173.
- Delfraissy, J.-F., Flandre, P., Delaugerre, C., Ghosn, J., Horban, A., Girard, P.-M., dkk., 2008. Lopinavir/Ritonavir Monotherapy or Plus Zidovudine and Lamivudine in Antiretroviral-Naive HIV-Infected Patients. *AIDS*, **22**: 385–393.
- Depkes RI, 2004. *Keputusan Menteri Kesehatan Republik Indonesia Tentang Standar Pelayanan Farmasi Di Rumah Sakit*. Departemen Kesehatan RI, Jakarta.
- Direktorat Bina Farmasi Komunitas dan Klinik, 2006. *Pedoman Pelayanan Kefarmasian Untuk Orang Dengan HIV/AIDS (ODHA)*. Direktorat Bina Farmasi Komunitas dan Klinik, Ditjen Bina Kefarmasian dan Alat Kesehatan, Departemen Kesehatan RI, Jakarta.
- Ditjen PPM&PL, 2004. *Pedoman Nasional Terapi Antiretroviral*. Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan Lingkungan, Departemen Kesehatan RI, Jakarta.
- Ditjen PP&PL, 2008. 'Statistik Kasus HIV/AIDS di Indonesia Dilaporkan Sampai dengan Desember 2007', *Yayasan Spiritia*. URL: <http://www.spiritia.or.id/Stats/Statistik.php> (diakses tanggal 4/2/2018).
- Ditjen PP&PL, 2017. 'Statistik Kasus HIV/AIDS di Indonesia Dilaporkan Sampai dengan Desember 2016', *Yayasan Spiritia*. URL: <http://www.spiritia.or.id/Stats/Statistik.php> (diakses tanggal 4/2/2018).
- Dooley, K.E., Flexner, C., dan Andrade, A.S., 2008. Drug Interactions Involving Combination Antiretroviral Therapy and Other Anti-Infective Agents: Repercussions for Resource-Limited Countries. *The Journal of Infectious Diseases*, **198**: 948–961.
- Drugs.com, 2018. 'Drug Interaction Report', *Drugs.com*. URL: [https://www.drugs.com/interactions-check.php?drug\\_list=276-0,1096-0,1484-0,1605-0,2012-0,2067-0,1863-15957&professional=1](https://www.drugs.com/interactions-check.php?drug_list=276-0,1096-0,1484-0,1605-0,2012-0,2067-0,1863-15957&professional=1) (diakses tanggal 12/3/2018).
- Duval, X., Journot, V., Leport, C., Cheˆne, G., Dupon, M., Cuzin, L., dkk., 2004. Incidence of and Risk Factors for Adverse Drug Reactions in a Prospective Cohort of HIV-Infected Adults Initiating Protease Inhibitor-Containing Therapy. *Clinical Infectious Diseases*, **39**: 248–255.
- Ehrenpreis, E.D., Roginsky, G., Alexoff, A., dan Smith, D.G., 2017. Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database. *Journal of Clinical Gastroenterology*, **51**: 56–62.

- Eluwa, G.I., Badru, T., dan Akpoigbe, K.J., 2012. Adverse Drug Reactions to Antiretroviral Therapy (ARVs): Incidence, Type and Risk Factors in Nigeria. *BMC Clinical Pharmacology*, **12**: 1–9.
- Epstein, F.H., Pantaleo, G., Graziosi, C., dan Fauci, A.S., 1993. The Immunopathogenesis of Human Immunodeficiency Virus Infection. *New England Journal of Medicine*, **328**: 327–335.
- Evans, S.R., Ellis, R.J., Chen, H., Yeh, T., Lee, A.J., Schifitto, G., dkk., 2011. Peripheral Neuropathy in HIV: Prevalence and Risk Factors. *AIDS*, **25**: 919–928.
- Fairall, L.R., Bachmann, M.O., Louwagie, G.M.C., Vuuren, C. van, Chikobvu, P., Steyn, D., dkk., 2008. Effectiveness of Antiretroviral Treatment in a South African Program, A Cohort Study. *Archives of Internal Medicine*, **168**: 86.
- Ferradini, L., Ouk, V., Segeral, O., Nouhin, J., Dulioust, A., Hak, C., dkk., 2011. High Efficacy of Lopinavir/r-based Second-Line Antiretroviral Treatment After 24 Months of Follow Up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. *Journal of the International AIDS Society*, **14**: 14.
- Finkelstein, J.L., Gala, P., Rochford, R., Glesby, M.J., dan Mehta, S., 2015. HIV/AIDS and Lipodystrophy: Implications for Clinical Management in Resource-limited Settings. *Journal of the International AIDS Society*, **18**: 1–22.
- Fletcher, C.V. dan Kakuda, T.N., 2005. Human Immunodeficiency Virus Infection. Dipro, J.T., Talbert, R.I., Yee, G.C., Maatzke, A., Wells, B.G., Passey, L.M., dalam: *Pharmacotherapy: A Pathophysiologic Approach*. Appleton and Lange, Philadelphia.
- Ford, N., Shubber, Z., Hill, A., Vitoria, M., Doherty, M., Mills, E.J., dkk., 2013. Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials. *PLoS ONE*, **8**: e79981.
- Gilks, C.F., Walker, A.S., Munderi, P., Kityo, C., Reid, A., Katabira, E., dkk., 2013. A Single CD4 Test with 250 Cells/mm<sup>3</sup> Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria. *PLoS ONE*, **8**: e57580.
- Gunda, D.W., Kidenya, B.R., Mshana, S.E., Kilonzo, S.B., dan Mpondo, B.C.T., 2017. Accuracy of WHO Immunological Criteria in Identifying Virological Failure among HIV-infected Adults on First Line Antiretroviral Therapy in Mwanza, North-western Tanzania. *BMC Research Notes*, **10**: 1–5.
- Hagblom, A., Santacatterina, M., Neogi, U., Gisslen, M., Hejdeman, B., Flamholz, L., dkk., 2017. Effect of Therapy Switch on Time to Second-Line Antiretroviral Treatment Failure in HIV-Infected Patients. *PLOS ONE*, **12**: e0180140.
- Hakim, J.G., Thompson, J., Kityo, C., Hoppe, A., Kambugu, A., van Oosterhout, J.J., dkk., 2017. Lopinavir Plus Nucleoside Reverse-Transcriptase Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for Second-Line Treatment of HIV (EARNEST): 144-Week Follow-up Results from a Randomised Controlled Trial. *The Lancet Infectious Diseases*, **18**: 47–57.



- Han, Y., Li, Yijia, Xie, J., Qiu, Z., Li, Yanling, Song, X., dkk., 2015. Week 120 Efficacy of Tenofovir, Lamivudine, and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients. *PLOS ONE*, **10**: e0120705.
- Hawkins, T., 2010. Understanding and Managing the Adverse Effects of Antiretroviral Therapy. *Antiviral Research*, **85**: 201–209.
- Hidayati, N.R., Abdillah, S., dan Keban, S.A., 2016. Analisis Adverse Drug Reactions Obat Antiretroviral pada Pengobatan Pasien HIV/AIDS di RSUD Gunung Jati Cirebon Tahun 2013. *Pharmaciana*, **6**: 79–88.
- Hughes, C.A., Foisy, M., dan Tseng, A., 2010. Interactions Between Antifungal and Antiretroviral Agents. *Expert Opinion on Drug Safety*, **9**: 723–742.
- Jamil, K.F., 2014. Profil Kadar CD4 terhadap Infeksi Oportunistik pada Penderita Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) Di RSUD Dr. Zainoel Abidin Banda Aceh. *Jurnal Kedokteran Syiah Kuala*, **14**: 76–80.
- Jensen-Fangel, S., 2004. The Effectiveness of Highly Active Antiretroviral Therapy in HIV-Infected Patients. *Dan Med Bull*, **51**: 371–92.
- Johnston, V., Cohen, K., Wiesner, L., Morris, L., Ledwaba, J., Fielding, K.L., dkk., 2014. Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. *The Journal of Infectious Diseases*, **209**: 711–720.
- Johnston, V., Fielding, K., Charalambous, S., Mampho, M., Churchyard, G., Phillips, A., dkk., 2012. Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome. *PLoS ONE*, **7**: e36997.
- Kemenkes RI, 2007. 'Keputusan Menteri Kesehatan Republik Indonesia tentang Penetapan Lanjutan Rumah Sakit Rujukan bagi Orang Dengan HIV dan AIDS (ODHA)', *Komisi Penanggulangan AIDS*. URL: [http://www.aidsindonesia.or.id/uploads/20130506131726.Skmenkes\\_Nomor\\_760\\_MENKES\\_SK\\_VI\\_2007\\_Tentang\\_Penetapan\\_Lanjutan\\_Rumah\\_Sakit\\_Rujukan\\_Bagi\\_Orang\\_Dengan\\_HIV\\_dan\\_AIDS\\_ODHA.pdf](http://www.aidsindonesia.or.id/uploads/20130506131726.Skmenkes_Nomor_760_MENKES_SK_VI_2007_Tentang_Penetapan_Lanjutan_Rumah_Sakit_Rujukan_Bagi_Orang_Dengan_HIV_dan_AIDS_ODHA.pdf) (diakses tanggal 6/2/2018).
- Kemenkes RI, 2012. *Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa dan Remaja*. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Kementerian Kesehatan RI, Jakarta.
- Kemenkes RI, 2015. *Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 tentang Pedoman Pengobatan Antiretroviral*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kouotou, E.A., Nansseu, J.R., Ngono, V.N., Tatah, S.A., Zoung-Kanyi Bissek, A.C., dan Ndjitoyap Ndam, E.C., 2017. Prevalence and Clinical Profile of Drug Eruptions among Antiretroviral Therapy-Exposed HIV Infected People in Yaoundé, Cameroon. *Dermatology Research and Practice*, **2017**: 1–6.

- KPAN, 2007. 'Strategi Nasional Penanggulangan HIV dan AIDS 2007-2010', *Yayasan Spiritia*. URL: <http://spiritia.or.id/dokumen/stranas07-10.pdf> (diakses tanggal 6/2/2018).
- KPAN, 2011. 'Rangkuman Eksekutif Upaya Penanggulangan HIV dan AIDS di Indonesia 2006 - 2011: Laporan 5 Tahun Pelaksanaan Peraturan Presiden No. 75/2006 tentang Komisi Penanggulangan AIDS Nasional', *Komisi Penanggulangan AIDS*. URL: <http://www.aidsindonesia.or.id/repo/ExSumLap5thnInd.pdf> (diakses tanggal 4/4/2018).
- KPAN, 2015. 'Strategi dan Rencana Aksi Nasional 2015-2019 Penanggulangan HIV dan AIDS di Indonesia', *Sistem Informasi HIV/AIDS&IMS Online Kemenkes RI*. URL: [siha.depkes.go.id/portal/files\\_upload/SRAN\\_2015\\_2019\\_FINAL.pdf](http://siha.depkes.go.id/portal/files_upload/SRAN_2015_2019_FINAL.pdf) (diakses tanggal 4/4/2018).
- Li, H., Marley, G., Ma, W., Wei, C., Lackey, M., Ma, Q., dkk., 2016. The Role of ARV Associated Adverse Drug Reactions in Influencing Adherence Among HIV-Infected Individuals: A Systematic Review and Qualitative Meta-Synthesis. *AIDS and Behavior*, **21**: 341–351.
- Li, M. dan Ramos, L.G., 2017. Drug-Induced QT Prolongation And Torsades de Pointes. *Pharmacovigilance Forum*, **42**: 473–477.
- Lim, M.L., Min, S.S., Eron, J.J., Bertz, R.J., Robinson, M., Gaedigk, A., dkk., 2004. Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **36**: 1034–1040.
- Low, A., Gavrilidis, G., Larke, N., B-Lajoie, M.-R., Drouin, O., Stover, J., dkk., 2016. Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*, **62**: 1595–1603.
- Luma, H.N., Doualla, M.-S., Choukem, S.-P., Temfack, E., Ashuntantang, G., Joko, H.A., dkk., 2012. Adverse Drug Reactions of Highly Active Antiretroviral Therapy (HAART) in HIV Infected Patients at the General Hospital, Douala, Cameroon: A Cross Sectional Study. *Pan African Medical Journal*, **12**: 1–7.
- Manosuthi, W., Wiboonchutikul, S., dan Sungkanuparph, S., 2016. Integrated Therapy for HIV and Tuberculosis. *AIDS Research and Therapy*, **13**: 1–12.
- Masenyetse, L.J., Manda, S., dan Mwambi, H.G., 2015. An Assessment of Adverse Drug Reactions Among HIV Positive Patients Receiving Antiretroviral Treatment in South Africa. *AIDS Research and Therapy*, **12**: 6.
- Mathis, S., Khanlari, B., Pulido, F., Schechter, M., Negredo, E., Nelson, M., dkk., 2011. Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis. *PLoS ONE*, **6**: e22003.
- May, M.T., Vehreschild, J.-J., Trickey, A., Obel, N., Reiss, P., Bonnet, F., dkk., 2016. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15

- Years After Start of Treatment: Collaborative Cohort Study. *Clinical Infectious Diseases*, **62**: 1571–1577.
- Mayer, K.H. dan Hamilton, C.D., 2010. Synergistic Pandemics: Confronting the Global HIV and Tuberculosis Epidemics. *Clinical Infectious Diseases*, **50**: S67–S70.
- Mehta, U. dan Maartens, G., 2007. Is It Safe to Switch between Efavirenz and Nevirapine in The Event of Toxicity? *The Lancet Infectious Disease*, **7**: 733–738.
- Moyle, G.J., Sabin, C.A., Cartledge, J., Johnson, M., Wilkins, E., Churchill, D., dkk., 2006. A Randomized Comparative Trial of Tenofovir DF or Abacavir as Replacement for a Thymidine Analogue in Persons with Lipoatrophy. *AIDS*, **20**: 2043–2050.
- Muhič, N., Mrhar, A., dan Brvar, M., 2017. Comparative Analysis of Three Drug–Drug Interaction Screening Systems Against Probable Clinically Relevant Drug–Drug Interactions: A Prospective Cohort Study. *European Journal of Clinical Pharmacology*, **73**: 875–882.
- Nila, A., 2012. 'Evaluasi Kejadian Efek Samping Neuropati Perifer dan Lipodistrofi pada Pasien HIV/AIDS yang Menggunakan Stavudin dalam Regimen Antiretroviral di Rumah Sakit Kanker Dharmais Jakarta', , *Tesis, M. Farm.*, . Universitas Indonesia, Depok.
- Nursalam dan Kurniawati, N.D., 2007. *Asuhan Keperawatan Pada Pasien Terinfeksi HIV/AIDS*. Salemba Medika, Jakarta.
- Nwabueze, S.A., Joe-Ikechebelu, N.N., Modebe, I.A., Adogu, P.O.U., dan Ele, P.U., 2013. Relationship Between Peripheral Neuropathy and Antiretroviral Drugs Used in the Management of Adult Human Immunodeficiency Virus Patients. *Journal of HIV & Human Reproduction*, **1**: 36–40.
- Onyedum, C.C., Iroezindu, M.O., Chukwuka, C.J., Anyaene, C.E., Obi, F.I., dan Young, E.E., 2013. Profile of HIV-infected Patients Receiving Second-line Antiretroviral Therapy in a Resource-limited Setting in Nigeria. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **107**: 608–614.
- Osinusi-Adekanmbi, O., Stafford, K., Ukpaka, A., Salami, D., Ajayi, S., Ndembu, N., dkk., 2014a. Long-Term Outcome of Second-Line Antiretroviral Therapy in Resource-Limited Settings. *Journal of the International Association of Providers of AIDS Care (JIAPAC)*, **13**: 366–371.
- Oumar, A.A., Diallo, K., Dembélé, J.P., Samaké, L., Sidibé, I., Togo, B., dkk., 2012. Adverse Drug Reactions to Antiretroviral Therapy: Prospective Study in Children in Sikasso (Mali). *The Journal of Pediatric Pharmacology and Therapeutics*, **17**: 382–388.
- Palombi, L., Marazzi, M.C., Guidotti, G., Germano, P., Buonomo, E., Scarcella, P., dkk., 2009. Incidence and Predictors of Death, Retention, and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability. *Clinical Infectious Diseases*, **48**: 115–122.



- Panel on Antiretroviral Guidelines for Adults and Adolescents, 2017. *Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV*. Department of Health and Human Services.
- Patel, D., Desai, M., Shah, A.N., dan Dikshit, R.K., 2013. Early Outcome of Second Line Antiretroviral Therapy in Treatment-Experienced Human Immunodeficiency Virus Positive Patients. *Perspectives in Clinical Research*, **4**: 215–220.
- Paton, N.I., Kityo, C., Hoppe, A., Reid, A., Kambugu, A., Lugemwa, A., dkk., 2014. Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. *New England Journal of Medicine*, **371**: 234–247.
- Perwira, I., 2015. 'Profilaksis Pra Paparan (PPRP) sebagai Alternatif Pencegahan Penularan HIV', *Kebijakan AIDS Indonesia*. URL: <http://www.kebijakanaidsendonesia.net/id/artikel/artikel-tematik/1378-profilaksis-pra-pajanan-pprp-sebagai-alternatif-pencegahan-penularan-hiv> (diakses tanggal 6/2/2018).
- Pettersen, J.A., Jones, G., Worthington, C., Krentz, H.B., Keppler, O.T., Hoke, A., dkk., 2006. Sensory Neuropathy in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients: Protease Inhibitor–Mediated Neurotoxicity. *Annals of Neurology*, **59**: 816–824.
- Pirmohamed, M., Atuah, K.N., Dodoo, A.N.O., dan Winstanley, P., 2007. Pharmacovigilance in Developing Countries. *BMJ*, **335**: 462–462.
- Pokala, N., Dixit, R., Manubhai, P.M., dan Vijayal, K., 2014. Adverse Drug Reactions with Second Line Antiretroviral Drug Regimen. *Asian Journal of Pharmaceutical and Clinical Research*, **7**: 75–79.
- Prasitsuebsai, W., Teeraananchai, S., Singtoroj, T., Truong, K.H., Ananworanich, J., Do, V.C., dkk., 2016. Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **72**: 380–386.
- Preston, C.L., Elaina E Crehan, Driver, S., Hatwal, C.S., Jones, S.L., Khan, S.Z., dkk., 2014. *Stockley's Drug Interactions Pocket Companion 2015*. Pharmaceutical Press, London.
- Pujades-Rodríguez, M., Balkan, S., Arnould, L., Brinkhof, M.A.W., dan Calmy, A., 2010. Treatment Failure and Mortality Factors in Patients Receiving Second-Line HIV Therapy in Resource-Limited Countries. *JAMA*, **304**: 303.
- Pusdatin Kemenkes RI, 2016. *Situasi Penyakit HIV/AIDS Di Indonesia*. InfoDATIN, Pusat Data dan Informasi Kementerian Kesehatan RI, Jakarta.
- Raffi, F., Babiker, A.G., Richert, L., Molina, J.-M., George, E.C., Antinori, A., dkk., 2014. Ritonavir-Boosted Darunavir Combined with Raltegravir or Tenofovir–Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1: 96 Week Results from the NEAT001/ANRS143 Randomised Non-Inferiority Trial. *The Lancet*, **384**: 1942–1951.
- Ramadhani, H.O., Bartlett, J.A., Thielman, N.M., Pence, B.W., Kimani, S.M., Maro, V.P., dkk., 2014. Association of First-Line and Second-Line Antiretroviral Therapy Adherence. *Open Forum Infectious Diseases*, **1**: ofu079–ofu079.

- Ramadhani, H.O., Bartlett, J.A., Thielman, N.M., Pence, B.W., Kimani, S.M., Maro, V.P., dkk., 2016. The Effect of Switching to Second-Line Antiretroviral Therapy on the Risk of Opportunistic Infections among Patients Infected with Human Immunodeficiency Virus in Northern Tanzania. *Open Forum Infectious Diseases*, **3**: ofw018.
- Reynes, J., Lawal, A., Pulido, F., Soto-Malave, R., Gathe, J., Tian, M., dkk., 2011. Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results. *HIV Clinical Trials*, **12**: 255–267.
- Reynes, J., Trinh, R., Pulido, F., Soto-Malave, R., Gathe, J., Qaqish, R., dkk., 2012. Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naïve Subjects: 96-Week Results of the PROGRESS Study. *AIDS Research and Human Retroviruses*, 120803082830003.
- Sattler, F.R., 2008. Pathogenesis and Treatment of Lipodystrophy : What Clinicians Need to Know. *Topics in HIV Medicine*, **16**: 127–133.
- Sears, D.W., 2009. 'Structure of HIV', *Biosci Portal*. URL: <https://biosci.mcdb.ucsb.edu/immunology/Immunodeficiencies/HIV-structure.htm> (diakses tanggal 21/3/2017).
- Shet, A., Antony, J., Arumugam, K., Kumar Dodderi, S., Rodrigues, R., dan DeCosta, A., 2014. Influence of Adverse Drug Reactions on Treatment Success: Prospective Cohort Analysis of HIV-Infected Individuals Initiating First-Line Antiretroviral Therapy in India. *PLoS ONE*, **9**: e91028.
- Soorju, V. dan Naidoo, P., 2016. Confirmation of Factors That Influence Antiretroviral Regimen Change and the Subsequent Patient Outcomes at a Regional Hospital in Rural Kwazulu-Natal. *African Journal of Primary Health Care & Family Medicine*, **8**: 1–6.
- Ssempijja, V., Nakigozi, G., Chang, L., Gray, R., Wawer, M., Ndyababo, A., dkk., 2017. Rates of Switching to Second-Line Antiretroviral Therapy and Impact of Delayed Switching on Immunologic, Virologic, and Mortality Outcomes Among HIV-Infected Adults with Virologic Failure in Rakai, Uganda. *BMC Infectious Diseases*, **17**: 1–10.
- Stockdale, A.J., Saunders, M.J., Boyd, M.A., Bonnett, L.J., Johnston, V., Wandeler, G., dkk., 2017. Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*, **XX**: 1–12.
- Sugiharti, S., Yuniar, Y., dan Lestary, H., 2014. Gambaran Kepatuhan Orang dengan HIV/AIDS (ODHA) dalam Minum Obat ARV di Kota Bandung, Provinsi Jawa Barat, Tahun 2011-2012. *Jurnal Kesehatan Reproduksi*, **5**: 11.
- Sunpath, H., Winternheimer, P., Cohen, S., Tennant, I., Chelin, N., Gandhi, R.T., dkk., 2014. Double-Dose Lopinavir-Ritonavir in Combination with Rifampicin-Based Anti-Tuberculosis Treatment in South Africa. *The International Journal of Tuberculosis and Lung Disease: The Official*

- Journal of the International Union Against Tuberculosis and Lung Disease*, **18**: 689–693.
- Tambunan, R., Kamil, O., Praptoraharjo, I., Erlan, H., dan Irwanto, 2010. 'Jaringan Seksual dan Penggunaan NAPZA pada Pengguna NAPZA Suntik di 6 Propinsi', *Komisi Penanggulangan AIDS*. URL: [www.aidsindonesia.or.id/repo/perpustakaan/jaringanseksidu.pdf](http://www.aidsindonesia.or.id/repo/perpustakaan/jaringanseksidu.pdf) (diakses tanggal 4/4/2018).
- Thao, V.P., Quang, V.M., Wolbers, M., Anh, N.D., Shikuma, C., Farrar, J., dkk., 2015. Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam. *Medicine*, **94**: e1715.
- Tisdale, J.E., 2016. Drug-Induced Qt Interval Prolongation and Torsades De Pointes. *Canadian Pharmacists Journal : CPJ*, **149**: 139–152.
- Truven Health Analytics, 2011. 'Lopinavir/ritonavir', *DynaMed Plus*. URL: <http://www.dynamed.com/topics/dmp~AN~T232794/Lopinavir-Ritonavir#Drug-Interactions> (diakses tanggal 12/3/2018).
- Tsegaye, A.T., Wubshet, M., Awoke, T., dan Addis Alene, K., 2016. Predictors of Treatment Failure on Second-Line Antiretroviral Therapy Among Adults in Northwest Ethiopia: A Multicentre Retrospective Follow-up Study. *BMJ Open*, **6**: e012537.
- UNAIDS, 2016a. 'Global AIDS Update 2016', *UNAIDS*. URL: [http://www.unaids.org/sites/default/files/media\\_asset/global-AIDS-update-2016\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf) (diakses tanggal 28/3/2018).
- UNAIDS, 2016b. 'AIDS by the Numbers, AIDS is Not Over, but It Can Be', . URL: [http://www.unaids.org/sites/default/files/media\\_asset/AIDS-by-the-numbers-2016\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-numbers-2016_en.pdf) (diakses tanggal 28/3/2018).
- UNAIDS, 2016c. 'Country Factsheets Indonesia 2016', *AIDSinfo*. URL: <http://aidsinfo.unaids.org/> (diakses tanggal 28/3/2018).
- Vadlapatla, R.K., Patel, M., Paturi, D.K., Pal, D., dan Mitra, A.K., 2014. Clinically Relevant Drug–Drug Interactions Between Antiretrovirals and Antifungals. *Expert Opinion on Drug Metabolism & Toxicology*, **10**: 561–580.
- Wandeler, G., Rohr, J., Chi, B.H., Orrell, C., Chimbetete, C., Prozesky, H., dkk., 2014. Tenofovir or Zidovudine in Second-Line Antiretroviral Therapy After Stavudine Failure in Southern Africa. *Antiviral Therapy*, **19**: 521–525.
- WHO, 2013a. *Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach*. World Health Organization, Geneva, Switzerland.
- WHO, 2013b. 'Summary of Key ARV Drug Interactions', *World Health Organization*. URL: [http://apps.who.int/iris/bitstream/10665/91047/1/WHO\\_HIV\\_2013.66\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/91047/1/WHO_HIV_2013.66_eng.pdf?ua=1) (diakses tanggal 3/12/2018).
- WHO, 2013c. 'How Accurately Do the WHO 2010 Immunological or Clinical Criteria Predict Virological Failure in Adults and Children Receiving ART?', *World Health Organization*. URL: [http://apps.who.int/iris/bitstream/handle/10665/91031/WHO\\_HIV\\_2013.4\\_3\\_eng.pdf?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/91031/WHO_HIV_2013.4_3_eng.pdf?sequence=1) (diakses tanggal 4/4/2018).



- Winarno, H., Suryoputro, A., dan Shaluhiah, Z., 2008. Faktor-Faktor yang Berhubungan dengan Penggunaan Jarum Suntik Bergantian di antara Pengguna NAPZA Suntik di Kota Semarang. *Jurnal Promosi Kesehatan Indonesia*, **3**: 74–85.
- Yasin, N.M., Maranty, H., dan Ningsih, W.R., 2011. Analisis Respon Terapi Antiretroviral pada Pasien HIV/AIDS. *Majalah Farmasi Indonesia*, **22**: 212–222.